Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Calibrium

Calibrium
2012 FOUNDED
M&A STATUS
M&A LATEST DEAL TYPE
Description

Developer of drugs for treatment of Diabetes. The company is developing a portfolio of novel drug candidates for the treatment of diabetes and related metabolic diseases.

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Acquirer
Primary Office
  • 11711 North Meridian Street
  • Suite 300
  • Carmel, IN 46032
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Calibrium’s full profile, request a free trial.

Calibrium Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 27-Aug-2015 00.000 Completed Generating Revenue
1. Convertible Debt 20-Dec-2013 00.000 00.000 Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

Calibrium Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
5AM Ventures Venture Capital Minority 000 0000 000000 0
BioCrossroads Venture Capital Minority 000 0000 000000 0
Frazier Healthcare Partners Venture Capital Minority 000 0000 000000 0

Calibrium Executive Team (6)

Name Title Board
Seat
Contact
Info
Jaswant Gidda Ph.D Vice President of Preclinical Development

5 Former Executives

You’re viewing 1 of 6 executives. Get the full list »